Phase III KATHERINE trial crossed early reporting boundary and met its primary endpoint
A phase III clinical trial showed that neoadjuvant chemotherapy and…
A phase III clinical trial showed that neoadjuvant chemotherapy and trastuzumab reduced the risk of recurrence of HER2-positive early-stage breast cancer...